Skip to main content

Table 4 Ocular toxicities

From: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Patient ID

AE (Preferred term)

Study day of onset

Duration (Days)

Severity

Relation to SGN-40

029-0010

Eye pain

1

4

Grade 1

Possibly

Eye pain

5

3

Grade 1

Possibly

Eye pain

8

4

Grade 1

Possibly

029-0011

Eye irritation

1

1

Grade 1

Possibly

Vision blurred

8

1

Grade 1

Possibly

044-0001

Conjunctivitis

5

14

Grade 2

Probably

Eye pain

11

11

Grade 2

Possibly

Eye infection

16

4

Grade 2

Unlikely

Orbital cellulitis (SAE)

18

4

Grade 3

Possibly

059-0001

Dry eye

16

8

Grade 2

Possibly

066-0010

Conjunctival irritation

16

22

Grade 1

Possibly

Eye pain

37

36

Grade 1

Possibly

066-0011

Conjunctival hyperaemia

4

11

Grade 2

Possibly

066-0005

Conjunctival hyperaemia

1

56

Grade 1

Unrelated

005-0002

Conjunctival hemorrhage

17

1

Grade 3

Unrelated